| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $10 t...
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.44) by 15...
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgi...
Craig-Hallum analyst Chase Knickerbocker maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $15 to ...
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.